We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Investigational Drug Traps Parasites Inside Their Hosts' Cells

By LabMedica International staff writers
Posted on 30 Jan 2013
A recent paper described the molecular pathways utilized by intracellular parasites such as Plasmodium falciparum and Toxoplasma gondii to survive in and escape from host cells and suggested that the investigational drug sotrastaurin may prove to effectively prevent infection by these pathogens.

Investigators at the University of Pennsylvania (Philadelphia, USA) and Johns Hopkins University (Baltimore, MD, USA) wrote in the January 16, 2013, issue of the journal Cell, Host and Microbe that they had identified a G-alpha-q-coupled host-signaling cascade required for the escape of both P. More...
falciparum and T. gondii from host cells. G-alpha-q-coupled signaling resulted in protein kinase C (PKC)-mediated loss of the host cytoskeletal protein adducin and weakening of the cellular cytoskeleton. This damage to the cytoskeleton induced catastrophic Ca2+ influx mediated by the cation channel TRPC6, which activated host calpain that proteolyzed the host cytoskeleton allowing parasite release.

Calpains have been implicated in apoptotic cell death, and appear to be an essential component of necrosis. Calpain is also involved in skeletal muscle protein breakdown due to exercise and altered nutritional states. Overexpression of calpain has been implicated as a factor in muscular dystrophy, AIDS, Alzheimer's disease, multiple sclerosis, and cancer.

Mammalian PKC inhibitors, such as sotrastaurin, have demonstrated activity in mouse models of malaria and toxoplasmosis. Furthermore, sotrastaurin prolonged survival in an experimental cerebral malaria model. Thise drug has already passed Phase I safety trials and is currently undergoing Phase II trials for various indications.

"We found an entire signaling pathway in the human host cell that the parasite engages, starting from a G-protein-coupled receptor, that the parasite uses to dismantle the cytoskeleton of the host cell, causing it to collapse," said senior author Dr. Doron Greenbaum, assistant professor of pharmacology at the University of Pennsylvania. "There is a complex series of proteins in this signaling cascade. One of the key proteins is protein kinase C (PKC). We found a tremendous amount of biological validation for the existence and use of this pathway in both parasitic organisms. PKC is a human enzyme that we are targeting, and by inhibiting it, we have basically blocked the parasites from getting out. They are trapped and die within the host cells."

"Targeting a host protein will engender less resistance because the parasite has no genetic control over the host," said Dr. Greenbaum. "We are quite excited about that. We have found a compound that is already been used in trials in humans and is deemed safe. This approach could be used as both a prophylactic and a treatment." Greenbaum says. "We have some indication that it could also be used to block transmission."

Related Links:
University of Pennsylvania
Johns Hopkins University



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.